PMID- 36044385
OWN - NLM
STAT- MEDLINE
DCOM- 20221209
LR  - 20221213
IS  - 2473-9537 (Electronic)
IS  - 2473-9529 (Print)
IS  - 2473-9529 (Linking)
VI  - 6
IP  - 23
DP  - 2022 Dec 13
TI  - A tumor volume and performance status model to predict outcome before treatment 
      in diffuse large B-cell lymphoma.
PG  - 5995-6004
LID - 10.1182/bloodadvances.2021006923 [doi]
AB  - Aggressive large B-cell lymphoma (LBCL) has variable outcomes. Current prognostic 
      tools use factors for risk stratification that inadequately identify patients at 
      high risk of refractory disease or relapse before initial treatment. A model 
      associating 2 risk factors, total metabolic tumor volume (TMTV) >220 cm3 
      (determined by fluorine-18 fluorodeoxyglucose positron emission tomography 
      coupled with computed tomography) and performance status (PS) >/=2, identified as 
      prognostic in 301 older patients in the REMARC trial (#NCT01122472), was 
      validated in 2174 patients of all ages treated in 2 clinical trials, PETAL 
      (Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas; 
      N = 510) and GOYA (N = 1315), and in real-world clinics (N = 349) across Europe 
      and the United States. Three risk categories, low (no factors), intermediate (1 
      risk factor), and high (2 risk factors), significantly discriminated outcome in 
      most of the series. Patients with 2 risk factors had worse outcomes than patients 
      with no risk factors in the PETAL, GOYA, and real-world series. Patients with 
      intermediate risk also had significantly worse outcomes than patients with no 
      risk factors. The TMTV/Eastern Cooperative Oncology Group-PS combination 
      outperformed the International Prognostic Index with a positive C-index for 
      progression-free survival and overall survival in most series. The combination of 
      high TMTV > 220 cm3 and ECOG-PS >/= 2 is a simple clinical model to identify 
      aggressive LBCL risk categories before treatment. This combination addresses the 
      unmet need to better predict before treatment initiation for aggressive LBCL the 
      patients likely to benefit the most or not at all from therapy.
CI  - (c) 2022 by The American Society of Hematology. Licensed under Creative Commons 
      Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), 
      permitting only noncommercial, nonderivative use with attribution. All other 
      rights reserved.
FAU - Thieblemont, Catherine
AU  - Thieblemont C
AUID- ORCID: 0000-0002-9941-2448
AD  - Hemato-oncologie, Universite de Paris, Hopital Saint-Louis, Assistance 
      Publique-Hopitaux de Paris (AP-HP), Paris, France.
FAU - Chartier, Loic
AU  - Chartier L
AD  - Statistique, Lymphoma Academic Research Organisation, Pierre-Benite, France.
FAU - Duhrsen, Ulrich
AU  - Duhrsen U
AD  - Hematology, Universitatsklinikum Essen, Essen, Germany.
FAU - Vitolo, Umberto
AU  - Vitolo U
AUID- ORCID: 0000-0001-7772-2747
AD  - Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, 
      Fondazione del Piemonte per l'Oncologia Istituto di Ricovero e Cura a Carattere 
      Scientifico, Candiolo, Italy.
FAU - Barrington, Sally F
AU  - Barrington SF
AUID- ORCID: 0000-0002-2516-5288
AD  - King's College London & Guy's and St Thomas' PET Centre, School of Biomedical 
      Engineering and Imaging Sciences, King's College London, London, United Kingdom.
FAU - Zaucha, Jan M
AU  - Zaucha JM
AD  - Poland and Polish Lymphoma Research Group, Medical University of Gdansk, Gdansk, 
      Poland.
FAU - Vercellino, Laetitia
AU  - Vercellino L
AD  - Medecine Nucleaire, Hopital Saint-Louis, AP-HP, Paris, France.
FAU - Gomes Silva, Maria
AU  - Gomes Silva M
AUID- ORCID: 0000-0002-6993-2450
AD  - Hematology, Instituto Portugues de Oncologia de Lisboa (IPO Lisboa), Lisboa, 
      Portugal.
FAU - Patrocinio-Carvalho, Ines
AU  - Patrocinio-Carvalho I
AUID- ORCID: 0000-0003-2523-4754
AD  - Nuclear Medecin, IPO Lisboa, Lisbon, Portugal.
FAU - Decazes, Pierre
AU  - Decazes P
AUID- ORCID: 0000-0001-5323-9910
AD  - Medecine Nucleaire, Centre Henri Becquerel, Rouen, France.
FAU - Viailly, Pierre-Julien
AU  - Viailly PJ
AD  - Institut National de la Sante et de la Recherche Medicale U1245, Centre Henri 
      Becquerel, Rouen, France.
FAU - Tilly, Herve
AU  - Tilly H
AD  - Institut National de la Sante et de la Recherche Medicale U1245, Centre Henri 
      Becquerel, Rouen, France.
FAU - Berriolo-Riedinger, Alina
AU  - Berriolo-Riedinger A
AUID- ORCID: 0000-0003-0771-7824
AD  - Medecine Nucleaire, Centre Hospitalier Universitaire (CHU) le Bocage, Dijon, 
      France.
FAU - Casasnovas, Oliver
AU  - Casasnovas O
AUID- ORCID: 0000-0002-1156-8983
AD  - Hematologie, CHU le Bocage, Dijon, France.
FAU - Huttmann, Andreas
AU  - Huttmann A
AUID- ORCID: 0000-0003-2230-3873
AD  - Hematology, Universitatsklinikum Essen, Essen, Germany.
FAU - Ilyas, Hajira
AU  - Ilyas H
AD  - King's College London & Guy's and St Thomas' PET Centre, School of Biomedical 
      Engineering and Imaging Sciences, King's College London, London, United Kingdom.
FAU - Mikhaeel, N George
AU  - Mikhaeel NG
AUID- ORCID: 0000-0003-0359-0328
AD  - Department of Clinical Oncology, Guy's & St Thomas' NHS Foundation Trust, School 
      of Cancer & Pharmaceutical Sciences, King's College London, London, United 
      Kingdom.
FAU - Dunn, Joel
AU  - Dunn J
AD  - King's College London & Guy's and St Thomas' PET Centre, School of Biomedical 
      Engineering and Imaging Sciences, King's College London, London, United Kingdom.
FAU - Cottereau, Anne-Segolene
AU  - Cottereau AS
AD  - Medecine Nucleaire, Hopital Cochin, AP-HP, Paris, France.
FAU - Schmitz, Christine
AU  - Schmitz C
AD  - Hematology, Universitatsklinikum Essen, Essen, Germany.
FAU - Kostakoglu, Lale
AU  - Kostakoglu L
AD  - Radiology and Medical Imaging, University of Virginia, Charlottesville, VA.
FAU - Paulson, Joseph N
AU  - Paulson JN
AD  - Department of Biostatistics, Genentech Inc, South San Francisco, CA.
FAU - Nielsen, Tina
AU  - Nielsen T
AD  - F. Hoffmann-La Roche Ltd, Basel, Switzerland.
FAU - Meignan, Michael
AU  - Meignan M
AD  - Lymphoma Study Association-Image Platform, Hopital Henri Mondor, Creteil, France.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Blood Adv
JT  - Blood advances
JID - 101698425
SB  - IM
MH  - Humans
MH  - Clinical Trials as Topic
MH  - *Lymphoma, Large B-Cell, Diffuse/diagnosis/drug therapy
MH  - Neoplasm Recurrence, Local
MH  - Tumor Burden
PMC - PMC9691911
COIS- Conflict-of-interest disclosure: C.T. received honoraria from Roche, Amgen, 
      Janssen, Celgene, and Gilead Science/Kyte; has been in a consulting/advisory role 
      for Roche, Gilead Sciences, Janssen, Celgene, and Novartis; and has received 
      research funding and travel, accommodations, and expenses from Roche and 
      Novartis. U.D. provided consultation to AbbVie, Amgen, CPT, Gilead/Kite, Janssen, 
      Novartis, and Takeda; has received research funding from Amgen, Celgene, and 
      Roche; and has received honoraria from AbbVie, Alexion, Amgen, Celgene, CPT, 
      Gilead/Kite, Janssen, Novartis, Roche, and Takeda. U.V. has received honoraria 
      from Roche and Janssen. J.M.Z. provided consultation to Novartis, Bristol Myers 
      Squibb, Takeda, Roche, and Sandoz; and received honoraria from Takeda, Roche, 
      AbbVie, and Sandoz. M.G.S. provided consultation to Roche, AbbVie, Bristol Myers 
      Squibb, Merck Sharp & Dohme, Janssen, and Gilead; has received research funding 
      from Gilead Sciences; and has received honoraria from Roche, Janssen, Gilead, and 
      AbbVie. O.C. has provided consultation to Roche, Takeda, Gilead, AbbVie, Merck 
      Sharp & Dohme, and Amgen; has received research funding from Roche, Gilead, and 
      Takeda; and has received honoraria from Roche, Takeda, Gilead, AbbVie, Merck 
      Sharp & Dohme, and Amgen. A.H. has received honoraria from Celgene, Gilead, and 
      Takeda. M.M. has provided consultation to and received honoraria from Roche. The 
      remaining authors declare no competing financial interests.
EDAT- 2022/09/01 06:00
MHDA- 2022/12/03 06:00
PMCR- 2022/09/02
CRDT- 2022/08/31 13:12
PHST- 2022/08/22 00:00 [accepted]
PHST- 2021/12/27 00:00 [received]
PHST- 2022/09/01 06:00 [pubmed]
PHST- 2022/12/03 06:00 [medline]
PHST- 2022/08/31 13:12 [entrez]
PHST- 2022/09/02 00:00 [pmc-release]
AID - 486458 [pii]
AID - 10.1182/bloodadvances.2021006923 [doi]
PST - ppublish
SO  - Blood Adv. 2022 Dec 13;6(23):5995-6004. doi: 10.1182/bloodadvances.2021006923.